Stock IPCALAB IPCA LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ipca Laboratories Limited Bombay S.E.

Equities

IPCALAB

INE571A01038

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:50 2024-04-26 am EDT 		5-day change 1st Jan Change
1,339 INR +0.82% Intraday chart for Ipca Laboratories Limited +0.14% +20.23%
Mar. 29 Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director CI
Mar. 29 Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director CI

Valuation

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 124,059 175,914 241,495 270,385 205,589 339,583 - -
Enterprise Value (EV) 1 126,717 179,826 239,835 275,070 201,870 350,130 344,171 335,473
P/E ratio 28 x 29.2 x 21.1 x 30.6 x 43.6 x 54.3 x 35.6 x 27.3 x
Yield 0.31% 0.36% 0.42% 0.75% 0.49% 0.35% 0.43% 0.49%
Capitalization / Revenue 3.29 x 3.78 x 4.46 x 4.64 x 3.29 x 4.48 x 3.82 x 3.33 x
EV / Revenue 3.36 x 3.87 x 4.43 x 4.72 x 3.23 x 4.62 x 3.87 x 3.29 x
EV / EBITDA 18.4 x 19.8 x 15.5 x 21 x 21.8 x 27 x 19.8 x 15.6 x
EV / FCF 40.6 x 69.7 x 32.9 x 72.9 x 64.8 x -27.9 x 51.3 x 37.9 x
FCF Yield 2.46% 1.43% 3.04% 1.37% 1.54% -3.58% 1.95% 2.64%
Price to Book 3.95 x 4.85 x 5.14 x 4.92 x 2.58 x 5.4 x 4.75 x 4.13 x
Nbr of stocks (in thousands) 252,704 252,704 253,704 253,704 253,704 253,704 - -
Reference price 2 490.9 696.1 951.9 1,066 810.4 1,338 1,338 1,338
Announcement Date 5/29/19 6/16/20 5/28/21 5/24/22 5/29/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 37,732 46,487 54,200 58,298 62,443 75,749 89,007 101,974
EBITDA 1 6,901 9,067 15,444 13,073 9,268 12,951 17,350 21,443
EBIT 1 5,076 6,962 13,352 10,748 6,652 9,768 13,418 16,957
Operating Margin 13.45% 14.98% 24.63% 18.44% 10.65% 12.9% 15.08% 16.63%
Earnings before Tax (EBT) 1 5,465 7,367 13,813 11,357 7,453 9,496 13,832 18,005
Net income 1 4,422 6,036 11,400 8,841 4,713 6,318 9,519 12,324
Net margin 11.72% 12.98% 21.03% 15.16% 7.55% 8.34% 10.69% 12.08%
EPS 2 17.50 23.86 45.06 34.85 18.58 24.66 37.63 49.11
Free Cash Flow 1 3,120 2,580 7,286 3,771 3,113 -12,550 6,705 8,861
FCF margin 8.27% 5.55% 13.44% 6.47% 4.99% -16.57% 7.53% 8.69%
FCF Conversion (EBITDA) 45.21% 28.45% 47.18% 28.85% 33.59% - 38.65% 41.32%
FCF Conversion (Net income) 70.55% 42.74% 63.91% 42.65% 66.06% - 70.44% 71.9%
Dividend per Share 2 1.500 2.500 4.000 8.000 4.000 4.638 5.716 6.616
Announcement Date 5/29/19 6/16/20 5/28/21 5/24/22 5/29/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 14,098 11,147 15,658 15,444 14,305 12,891 15,857 16,010 15,460 15,116 15,876 17,241 20,834 20,430
EBITDA 1 3,669 2,289 4,165 3,656 3,078 2,193 2,692 2,606 2,159 1,810 3,076 3,381 3,433 3,189
EBIT 1 3,134 1,764 3,607 3,086 2,491 1,584 2,075 1,969 1,493 1,115 2,384 2,791 2,376 1,904
Operating Margin 22.23% 15.83% 23.03% 19.98% 17.41% 12.29% 13.09% 12.3% 9.66% 7.38% 15.01% 16.19% 11.41% 9.32%
Earnings before Tax (EBT) 1 3,243 1,921 3,774 3,256 2,607 1,696 2,227 2,238 1,693 1,294 2,518 2,699 2,369 1,844
Net income 1 2,655 1,613 3,067 2,502 1,970 1,302 1,431 1,439 1,078 765.2 1,628 1,911 1,667 1,294
Net margin 18.83% 14.47% 19.59% 16.2% 13.77% 10.1% 9.02% 8.99% 6.98% 5.06% 10.26% 11.09% 8% 6.33%
EPS 2 10.54 6.355 12.09 9.865 7.760 5.130 5.640 5.670 4.250 3.020 6.420 7.100 5.675 -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/4/21 5/28/21 8/5/21 11/13/21 2/14/22 5/24/22 8/10/22 11/11/22 2/14/23 5/29/23 8/10/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,658 3,913 - 4,685 - 10,547 4,588 -
Net Cash position 1 - - 1,660 - 3,720 - - 4,110
Leverage (Debt/EBITDA) 0.3852 x 0.4315 x - 0.3584 x - 0.8144 x 0.2644 x -
Free Cash Flow 1 3,120 2,580 7,286 3,771 3,113 -12,550 6,705 8,861
ROE (net income / shareholders' equity) 15.2% 17.9% 27.4% 17.3% 8.34% 10.2% 13.9% 16%
ROA (Net income/ Total Assets) 10.2% 12.3% 20.1% 12.9% 5.8% 6.8% 12.6% -
Assets 1 43,340 49,054 56,641 68,536 81,249 92,909 75,665 -
Book Value Per Share 2 124.0 144.0 185.0 216.0 314.0 248.0 282.0 324.0
Cash Flow per Share 2 19.50 22.30 43.00 33.70 31.80 -13.40 41.00 47.50
Capex 1 1,805 3,063 3,616 4,790 4,945 19,321 4,336 4,171
Capex / Sales 4.78% 6.59% 6.67% 8.22% 7.92% 25.51% 4.87% 4.09%
Announcement Date 5/29/19 6/16/20 5/28/21 5/24/22 5/29/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ipca Laboratories Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
1,338 INR
Average target price
1,163 INR
Spread / Average Target
-13.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IPCALAB Stock
  4. IPCALAB Stock
  5. Financials Ipca Laboratories Limited